some have said reverse split coming....I see the company has it on agenda but
that doesn't mean it'll ever happen. Besides, it can come as late as the middle of 2014 and that's a LONG way off. Good news of both OM and T will come way before then. Bashers are so sneaky it's ridiculous in that they appear of good will but most certainly are not...I say bashers but really it's shorts that try most of the under the belt stuff. Can't say I blame them in that it is on Edgar and so gives their claim some credibility.
So someone who wants to alert other investors about the possibility of a reverse split is obviously a basher or is shorting the stock? Great logic there. It couldn't possibly be for any other reason, like maybe to pointi out something any halfway intelligent investor would want to know, right? I mean, most investors would prefer to stay ignorant of things that could potentially affect their investment. Makes sense.
An R/S might not come, but the possibility absolutely exists, and I'm betting that it does come, simply because the cost of upcoming trials will be massive without a partner and raising cash at a higher PPS makes more sense than doing so at a lower one. Happens all the time in early stage biotechs. The argument that they were only going to R/S to avoid a delisting is a weak one, and for anyone paying attention CYTK management hasn't been exactly all that shareholder friendly in the past.
I believe that was when back in Dec/2012 the company received a De-Listing notice from NASDAQ due to trading under $1...... but since ...
Jan 25, 2013
"SOUTH SAN FRANCISCO, Calif. (AP) -- Drug developer Cytokinetics Inc. said Friday that it has regained compliance with Nasdaq rules, as its shares have been trading above $1 for the last few weeks.
Shares of Cytokinetics closed under $1 every trading day from May 3 to Jan. 9. The Nasdaq Stock Market sent the company a warning letter in June saying its shares could be taken off the index because of their low price. Cytokinetics transferred its listing to the Nasdaq Capital Market in December. It had until June to regain compliance with the stock price rule.
The company said Nasdaq considers the matter closed.
Cytokinetics shares have climbed 50 percent since Jan. 3. The stock fell 2 cents to close at $1.05 Friday.
Cytokinetics' most advanced drug is omecamtiv mecarbil, which is being studied as a treatment for heart failure."
I think I said I don't blame you...CYTK seems to be its own worst enemy at times. Wait to see how T and OM are perceived by the FDA and then go from there. What's the point of doing the split and having shares to issue for money raising purposes when the science is flawed. If CYTK plays it right (in my opinion), it will wait till further research is completed and either of their major drugs are going to cut the muster....if so, reverse split...probably splitting off of a price of 4 to 6 bucks and able to raise a very meaningful amount of cash to bring one or both to market. This is where the CEO shows he has leadership and mentality to make CYTK far bigger than it is now.